Nautilus Biotechnology Stock Analysis - Price Action Indicator
| NAUT Stock | USD 2.88 -0.06 -2.04% |
Price Action Indicator measures where the close finished relative to the open, high, and low, capturing the session's directional conviction.
Price Action Indicator Analysis Today
Price Action Indicator measures where the close finished relative to the open, high, and low, capturing the session's directional conviction. The current Price Action Indicator for Nautilus Biotechnology is -0.1. This reading indicates elevated price movement across the session.| Volatility | Backtest | Information Ratio |
Nautilus Biotechnology Trading Date Momentum
| On May 07 2026 Nautilus Biotechnology was traded for 2.88 at the closing time. The top price for the day was 3.05 and the lowest listed price was 2.84 . The trading volume for the day was 169.2 K. The trading history from May 7, 2026 remained within defined bounds. The trading delta at closing time against the current closing price is 4.17% . |
Developed by Michael B. Geraty (Futures magazine, August 1997), PAIN aligns with Japanese candlestick interpretation — the magnitude reflects the strength of the session's directional conviction.
| Compare Nautilus Biotechnology to competition |
Related Price-Series Methods for Nautilus Biotechnology
These methods summarize the same price history through smoothing, range, and momentum calculations. Reviewing them alongside Price Action Indicator helps compare stable sessions with periods of wider price movement in Nautilus Biotechnology.Nautilus Biotechnology Related Equities
Investors studying Nautilus Biotechnology often look at related stocks within the Health Care space to gauge pricing and results. Key comparison metrics include price-to-earnings, profit margin, and revenue growth across Nautilus Biotechnology's peer group. How Nautilus Biotechnology ranks within this group can shift over time as the competitive picture changes. This type of review is most informative when done often to track how positions shift over time.
| Risk & Return | Correlation |
Nautilus Biotechnology Market Strength Events
Market strength indicators for Nautilus Biotechnology quantify how the stock responds to shifts in volume and sentiment. These indicators capture shifts in momentum that may precede significant price moves in Nautilus Biotechnology. The Market Facilitation Index measures how efficiently price moves relative to volume — rising MFI with rising volume signals strong trend participation. Monitoring these indicators for Nautilus Biotechnology through complete market cycles reveals recurring patterns.
Nautilus Biotechnology Risk Indicators
Analyzing Nautilus Biotechnology's risk indicators separates symmetric price swings from asymmetric downside exposure. Understanding and quantifying the risks present in Nautilus Biotechnology helps place recent price behavior in context. These metrics are most informative when compared against similar equities with comparable growth profiles and market capitalization. When semi-deviation is high relative to standard deviation, Nautilus Biotechnology's losses have been disproportionately large compared to gains.
| Mean Deviation | 4.53 | |||
| Semi Deviation | 5.08 | |||
| Standard Deviation | 6.43 | |||
| Variance | 41.4 | |||
| Downside Variance | 30.86 | |||
| Semi Variance | 25.8 | |||
| Expected Short fall | -5.16 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Nautilus Biotechnology Short Properties
Short-interest signals around Nautilus Biotechnology reveal whether skeptical positioning is starting to pressure price predictability and market tone. This is applicable when the question is whether bearish pressure is starting to shape the market's reaction function.
| Common Stock Shares Outstanding | 126.26 million | |
| Cash And Short Term Investments | 103.41 million |